Efficacy and safety of fluoxetine monotherapy in bipolar depression: A systematic review

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 8, 2013, Pages 1065-1075

  Martinotti, Giovanni ^a   Sepede, Gianna ^a   Signorelli, Maria ^b   Aguglia, Eugenio ^b   Di Giannantonio, Massimo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bipolar depression; Bipolar disorder; Fluoxetine; Mood switch

Indexed keywords

FLUOXETINE; IMIPRAMINE; LITHIUM; OLANZAPINE; PLACEBO; VALPROIC ACID;

AGITATION; ANOREXIA; BIPOLAR DEPRESSION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MOOD; MUSCLE TONE; MYALGIA; NAUSEA; NERVOUSNESS; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; FLUOXETINE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84877678379     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.783014     Document Type: Review

References (44)

1. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009;11:225-55
2. Grunze H, Vieta E, Goodwin GM, et al. The world federation of societies of biological psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81-109
3. Cruz N, Vieta E. Antidepressants in acute bipolar depression: An inconclusive meta-Analysis. J Clin Psychiatry 2011;72:415-16
4. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: A report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012;262(Suppl 1):1-48
5. Srivastava S, Ketter TA. Clinical relevance of treatments for acute bipolar disorder: Balancing therapeutic and adverse effects. Clin Ther 2011;33(12):B40-8
6. Connolly KR, Thase ME. The clinical management of bipolar disorder: A review of evidence-based guidelines. Prim Care Companion CNS Disord 2011;13(4):pii: PCC.10r01097-doi: 10.4088/PCC.10r01097
7. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009;166:164-72
8. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study. J Clin Psychiatry 2000;61:804-8
9. Rossi A, Barraco A, Donda P. Fluoxetine: A review on evidence based medicine. Ann Gen Hosp Psychiatry 2004;3:2
10. Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009;5:369-83
11. Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12(17):2751-8
12. Bobo WV, Epstein RA Jr, Shelton RC. Acute bipolar depression: A review of the use of olanzapine/fluoxetine. Clin Med Insights Ther 2010;2:825-40. doi: 10.4137/CMT.S1945
13. Deeks ED, Keating GM. Olanzapine/ fluoxetine: A review of its use in the treatment of acute bipolar depression. Drugs 2008;68(8):1115-37
14. Brunswick DJ, Amsterdam JD, Fawcett J, et al. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy. J Clin Psychopharmacol 2001;21:616-18
15. Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opin Drug Saf 2004;3:495-504
16. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4(4):313-22
17. Simpson SG, DePaulo Jr. Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991;11(1):52-4
18. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18(6):435-40
19. Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-Term fluoxetine monotherapy for bipolar Type II or bipolar NOS major depression -low manic switch rate. Bipolar Disord 2004;6(1):75-81
20. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar Type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005;20(5):257-64
21. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar Type I and Type II major depression-lack of manic induction. J Affect Disord 2005;87(1):121-30
22. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-Term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 2010;30(3):306-11
23. Amsterdam JD, Shults J. Efficacy and safety of long-Term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010;167(7):792-800
24. Amsterdam JD, Luo L, Shults J. Efficacy and mood conversion rate during long-Term fluoxetine v. lithium monotherapy in rapid-And non-rapid-cycling bipolar II disorder. Br J Psychiatry 2012; Epub ahead of print
25. Malhi GS, Adams D, Lampe L, et al. Northern Sydney Central Coast Mental Health Drug & Alcohol; NSW Health Clinical Redesign Program; CADE Clinic, University of Sydney. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009(439):27-46
26. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012;14(Suppl 2):37-50
27. Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: Comprehensive meta-Analytic review. Acta Psychiatr Scand 2010;121(6):404-14; Epub 2009 Dec 2
28. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12
29. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-9
30. Fonseca M, Soares JC, Hatch JP, et al. An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry 2006;67:81-6
31. Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. J Clin Psychopharmacol 2012;32:487-91
32. Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: An open-label study. J Biol Regul Homeost Agents 2011;25:109-14
33. Sepede G, Corbo M, Fiori F, Martinotti G. Reboxetine in clinical practice: A review. Clin Ther 2012;163:e255-62
34. Farina B, Della Marca G, Mennuni G, et al. The effects of reboxetine on human sleep architecture in depression: Preliminary results. J Affect Disord 2002;71:273-5
35. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: Identification of risk factors. J Clin Psychiatry 2001;62(4):249-55
36. Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 2010;35(13):2545-52
37. Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008;23:417-24
38. Sepede G, De Berardis D, Campanella D, et al. Impaired sustained attention in euthymic bipolar disorder patients and non-Affected relatives: An fMRI study. Bipolar Disord 2012;14:764-79
39. Mandelli L, Mazza M, Di Nicola M, et al. Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: Harm avoidance influences medium-Term treatment outcome. Psychopathology 2012;45:174-8
40. Mandelli L, Mazza M, Martinotti G, et al. Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. J Affect Disord 2009;119:205-9
41. Feighner JP, Boyer WF, Merideth CH, Hendrickson GG. A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989;4(2):127-34
42. Emslie GJ, Rush AJ, Weinbert WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7
43. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-47
44. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993;3(2):143-52